NAYA Biosciences Corp - Margin operasi NAYA

Logo korporat perusahaan NAYA Biosciences (NAYA)

The absence of commercial revenue due to the early stages of monoclonal drug research shifts NAYA Biosciences (NAYA) growth into the realm of R&D expenditures. The operating profit margin reflects this specificity, where -90.90 represents the latest value. Business stability relies on innovative bioplatforms and mergers in the US, although risks of test failures and a total dependence on speculative investments persist.

NAYA: Rentabilitas kegiatan operasi NAYA Biosciences Inc. 04.07.2022 - 28.04.2025

NAYA (NAYA Biosciences): rincian analitis lan laporan miturut indikator

Analisis komprehensif perusahaan:NAYA Biosciences Corp, NAYA
Barang utama NAYA Biosciences Corp

For NAYA Biosciences, which invests in a staff of biologists and clinical trials, the operating margin serves as a metric for the efficiency of R&D cost management. An analysis of the EBIT margin allows for an assessment of the share of operating profit before taxes and interest, demonstrating how successfully the innovative business model converts resources into revenue while excluding the impact of debt load and one-off market fluctuations.

Analisis pesaing

Rentabilitas operasi BeiGene Ltd|Halozyme Therapeutics - Margin bathi operasi|Margin dodolan operasi RVMD (Revolution Medicines Corp)|Rasio bathi operasi AAPG|Rentabilitas operasi CG Oncology Therapeutics CGON|Tingkat bathi operasi URGN|BCAX: Margin dodolan operasi|PSNL: Rentabilitas operasi|Erasca (ERAS) - Rentabilitas operasi|DCTH - Rentabilitas kegiatan operasi|YMAB (Y-mAbs Corp) - Margin operasi|Margin dodolan operasi Aura Biosciences (AURA)|Rentabilitas operasi Candel Therapeutics Inc. (CADL)|Margin dodolan operasi Accuray, Inc. ARAY|Rentabilitas operasi sellaslifesciences.com SLS|Tingkat bathi operasi ACTU|CTOR - Rentabilitas operasi|Rentabilitas kegiatan operasi tuhurabio.com HURA|Protara Therapeutics, Inc. (TARA) - Rentabilitas operasi|FATE: Rasio bathi operasi|WHWK (Aadi Bioscience, Inc.) - Margin operasi|TCRX (TScan Therapeutics) - Rasio bathi operasi|Rentabilitas operasi Champions Oncology (CSBR)|Rentabilitas kegiatan operasi XBiotech USA|Rentabilitas operasi CEL-SCI CVM|OS Therapies, Inc. (OSTX) - Rentabilitas dodolan operasi|RADX - Rentabilitas operasi|ARTV - Margin operasi|Adlai Nortye Ltd (ANL) - Rentabilitas operasi|Veru Pharma - Tingkat bathi operasi|Rentabilitas operasi Tempest Therapeutics Corp|Rentabilitas dodolan miturut bathi operasi XLO (Xilio Therapeutics, Inc.)|Margin operasi RENB|MURA (Mural Oncology) - Tingkat bathi operasi|Margin operasi KAPA (Kairos Pharma Ltd)|OKUR: Rentabilitas dodolan miturut bathi operasi|GDTC: Margin dodolan operasi|CRIS - Margin operasi|APLM: Margin operasi|Rentabilitas dodolan operasi tharimmune.com (THAR)|ADVB (Advanced Biomed Corp) - Margin operasi|Margin operasi Genprex Inc.|Margin operasi CLDI|Margin dodolan operasi Sunshine Biopharma, Inc. SBFM|Margin operasi XBIO (Xenetic Biosciences)|Tingkat bathi operasi SLRX|PPBT - Rentabilitas operasi|AONC (aoncology.com) - Rentabilitas dodolan miturut bathi operasi|BGNE: Margin operasi|Checkpoint Therapeutics Inc (CKPT) - Margin operasi|ELEV (Elevation Oncology Inc.) - Margin operasi|icadmed.com (ICAD) - Rentabilitas kegiatan operasi|Margin operasi IKNA|NTBL (Notable Labs) - Tingkat bathi operasi|Margin operasi VIRX (Viracta Therapeutics)|Rentabilitas kegiatan operasi MorphoSys AG (MOR)|Ascentage Pharma Group International - Margin operasi